GIMBHI’s daily mental health update — 10/01/26

🥗 Virtual SUD platform Nosis launches to address lifestyle and metabolic needs in recovery (Anastassia Gliadkovskaya, Fierce Healthcare) — 09/22/26
TL;DR: Nosis launched nationwide with a biomarker-driven, 12-week lifestyle program pairing peer health coaches and dietitians to tackle nutrition, sleep, and metabolic drivers of substance use recovery.

🧠 Pelago launches unified behavioral health platform with voice-first clinical AI Sona (Pelago) — 09/22/26
TL;DR: Pelago unified substance use, mental health, and behavioral addiction care under one contract powered by Sona, its clinical AI, which cut PHQ-9/GAD-7 scores by 5+ points in nearly half of users within a month.

🧠 ReEmerge raises $37M Series A to advance thalamic deep brain stimulation for TBI (Dominic Borkelmans, Neurofounders) — 09/22/26
TL;DR: Minnesota-based ReEmerge emerged from stealth with $37M co-led by U.S. Venture Partners and Santé to run a 40-patient multicenter trial of Cognitive Network Restoration Therapy for chronic moderate-to-severe traumatic brain injury.

💊 Kasvu Therapeutics raises €30M Series A to advance TrkB potentiator for depression (Kasvu Therapeutics) — 09/24/26
TL;DR: Helsinki-based Kasvu closed a €30M Series A led by Hadean Ventures to advance KTX-0141, a non-hallucinogenic neuroplastogen targeting TrkB for major depressive disorder, with Phase 1/1b trials expected in H2 2027.